The new National Authority for Scientific Research (NASR) will receive AED 100 million ($27 million) per year from the UAE government. Part of the Ministry and Higher Education and Scientific Research, the NASR was started in order for the UAE to be recognized by the international scientific community and to promote scientific research through cooperation […]
R&D spending may be on the rise in Turkey due to a new measure that lets companies deduct all of their R&D spending from their tax base until 2024, an increase from the previously allowed 40% tax deduction. The law was passed to stimulate exports of technological products and to attract multinational R&D. To be […]
Uganda’s parliament is set to review the country’s first National Biotechnology and Biosafety Policy, which was passed by the nation’s cabinet on April 2. Along with granting commercialization rights to GM crops, if passed, the law could regulate medical diagnostics, industrial microbiology and biochemical engineering. However, the approval for research of GM crops has been […]
The EU is continuing its focus on maintaining its position as a top ranking R&D region. According to Eurostat, the UK, Germany and France were responsible for approximately 60% of total R&D expenditure in the EU in 2006. For that year, 1.84% of the EU’s GDP, €212 billion ($265 billion), was spent on R&D. The […]
The credit crisis could affect the ability of biotech companies worldwide to raise new funding. Although venture capital funding for biotech did not slow last year, some observers believe the criteria for such investments will become stricter and competition between late- and early-stage companies for such funding could increase. Last year, funding for biotech and […]
According to the “2008 Pharmaceutical Industry Profile” released by the Pharmaceutical Research and Manufacturers of America (PhRMA), R&D spending by PhRMA-member companies rose 2.5% to $44.530 billion in 2007. Member companies’ 2007 sales increased 6.6% to $271.515 billion. As a result, R&D as a percentage of sales was 16.4%, down from 17.1% in 2006. In […]
In regards to corporate earnings, most investors focus their attention on sales and either net income or earnings per share (EPS). While sales figures are usually straightforward, EPS results are often reported in both GAAP (Generally Accepted Accounting Principles) and nonGAAP adjustments. GAAP results provide a standardized and consistent method to compare results, but do […]
Going into this year’s Analytica, the confidence level for a successful event was not particularly high, as signs of negativity seemed unmistakable. After all, talks of a recession in the US and the low dollar could deter many US-based companies from attending the show. The previous Analytica, which was two years ago (see IBO 4/30/06), […]
Global food sales grew an average of 1.8% last year, hampered by price increases for most staple items, including milk, eggs, corn and wheat. Food producers have also been impacted by higher electricity and fuel costs, part of what one analyst described as a “perfect storm” for the industry. In 2007, Kraft spent $1.3 billion […]
Two new reports released by Sense About Science and the Association of Clinical Biology, and the Royal College of Pathologists and the PHG Foundation address the need for government oversight of diagnostic testing kits and the potential for misdiagnoses. The reports on the heels of a Science Council report released at the end of January […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
